Incyte (INCY) | Stock Overview & Key Data
Incyte Performance Comparison
Stock Range
Today's Range
Low: $86.17
High: $88.66
on October 2, 2025
52 Week Range
Low: $53.56
High: $88.66
on April 9, 2025
on October 2, 2025
All-Time High: $153.15 on March 13, 2017
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$16.4B
EPS
4.29
P/E Ratio (TTM)
19.55
Forward P/E
13.66
P/B Ratio
3.90
PEG Ratio
-0.10
Div. Yield
N/A
ROE
24.30%
Beta
0.754
Debt to Equity
1.02
Financial Highlights
Profitability
Gross Margin
93.52%
Operating Margin
25.63%
Profit Margin
18.99%
Returns and Earnings
Return on Assets (TTM)
11.52%
Return on Equity (TTM)
24.30%
EBITDA
$1.2B
Net Income (TTM)
$870.9M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$23.70
Quarterly Revenue Growth (YoY)
16.50%
Quarterly Earnings Growth (YoY)
16.46%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Incyte INCY | 16.38B Large-cap | 5.66% | 0.35% | 26.57% | 38.42% | 24.09% | 27.84% | 26.10% | -9.88% |
| Vertex VRTX | 100.41B Large-cap | 7.07% | 1.96% | -10.54% | -15.44% | 0.76% | -10.20% | 38.49% | 51.45% |
| Alnylam ALNY | 60.43B Large-cap | 2.54% | 3.13% | 39.79% | 72.77% | 97.32% | 72.02% | 135.43% | 213.60% |
| Regeneron REGN | 59.93B Large-cap | 8.01% | 3.82% | 9.54% | -4.09% | -16.11% | -40.76% | -16.94% | -0.34% |
| Insmed INSM | 29.94B Large-cap | 12.69% | 5.16% | 55.54% | 108.06% | 118.44% | 111.43% | 591.72% | 323.86% |
| Royalty Pharma plc RPRX | 21.04B Large-cap | 4.56% | 0.88% | 0.83% | 16.66% | 41.49% | 31.50% | -10.70% | -17.22% |
Ownership & Short Interest
Insider Ownership
2.03%
Institutional Ownership
103.46%
Shares Short
9M
Short Ratio
5.16
Short % of Shares Outstanding
6.29%
Average 10-Day Volume
2M
Average 90-Day Volume
2M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is INCY's 52-week high and low?
- In the last 52 weeks, Incyte reached a high of $88.66 (on October 2, 2025) and a low of $53.56 (on April 9, 2025).
- What is the market cap and P/E ratio for INCY?
- Curious about Incyte's size and valuation? Its market capitalization stands at 16.38B. When it comes to valuation, the P/E ratio (trailing twelve months) is 19.55, and the forward P/E (looking ahead) is 13.66.
- Does INCY pay dividends? If so, what's the yield?
- As for dividends, Incyte isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Incyte's main competitors or similar companies to consider before investing?
When looking at Incyte, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX100.41B Healthcare Biotechnology -10.20% 38.49% Alnylam
ALNY60.43B Healthcare Biotechnology 72.02% 135.43% Regeneron
REGN59.93B Healthcare Biotechnology -40.76% -16.94% Insmed
INSM29.94B Healthcare Biotechnology 111.43% 591.72% Royalty Pharma plc
RPRX21.04B Healthcare Biotechnology 31.50% -10.70% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Incyte Corporation? (e.g., ROE, Debt/Equity)
- To get a sense of Incyte's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 24.30%, the Debt to Equity ratio from the most recent quarter is 1.02, and its Gross Profit Margin stands at 93.52%.
- What is the recent revenue and earnings growth for INCY?
- Looking at Incyte's growth, its revenue over the trailing twelve months (TTM) was $5B. Compared to the same quarter last year (YoY), quarterly revenue grew by 16.50%, and quarterly earnings saw a YoY growth of 16.46%.
- How much of INCY stock is held by insiders and institutions?
- Wondering who owns Incyte stock? Company insiders (like executives and directors) hold about 2.03% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 103.46%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.